早期肌缩侧面硬化症患者的淋巴功能障碍
Shuangwu Liu1,2,3, Xiaohan Sun2, Qingguo Ren4
1School of Nursing and Rehabilitation, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.
Brain : a journal of neurology
|August 16, 2023
概括
用ALPS指数衡量的淋巴系统功能障碍在早期肌缩侧面硬化症 (ALS) 患者中受损. 这种功能障碍与临床残疾和睡眠问题相关,表明ALS的潜在诊断和治疗点.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 生物医学成像技术 生物医学成像技术
背景情况:
- 淋巴系统,一个由天体细胞水素4-依赖的大脑排水通路,对于废物清理至关重要.
- 淋巴功能障碍与神经退行性疾病 (如阿尔茨海默氏症和帕金森症) 有关.
- 早期的淋巴功能障碍被怀疑是肌缩性侧面硬化症 (ALS),但在早期患者的体内研究缺乏.
研究的目的:
- 在早期的ALS患者中研究淋巴功能,使用ALPS指数.
- 评估ALPS指数在区分早期ALS与健康对照中的诊断性能.
- 探索早期ALS中淋巴功能障碍,临床残疾和睡眠障碍之间的关系.
主要方法:
- 追溯性研究涉及56名早期ALS患者 (国王阶段1) 和32名健康对照.
- 沿周血管空间 (ALPS) 指数进行扩散张力成像分析,以大致估计淋巴功能.
- 睡眠评估包括匹兹堡睡眠质量指数,爱普沃思睡眠度量表和多睡眠图.
主要成果:
- 与健康对照组相比,早期的ALS患者的ALPS指数明显较低 (P <0.05).
- ALPS指数显示出良好的诊断性能,曲线下的面积为0.792.
- ALPS指数与临床残疾和睡眠障碍有显著的相关性,睡眠效率和睡眠指数中的定期四肢运动是显著的预测因素.
结论:
- 淋巴功能障碍在早期的ALS病理学中起着重要作用.
- ALPS指数显示了作为ALS早期诊断生物标志物的潜力.
- 向改善淋巴功能可能是减缓ALS进展的治疗策略.
相关概念视频
Cross-bridge Cycle
117.7K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
117.7K
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Myasthenia Gravis: Overview and Treatment
1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K


